Covid-19
Britain investigates AstraZeneca-Alexion deal on competition concerns
Britain’s Competition and Markets Authority (CMA) has started its investigation into whether AstraZeneca’s takeover of Alexion Pharmaceuticals can reduce competition for products and services in the United Kingdom or any other markets.
The British competition regulator invites comments on the transaction from any interested party to assist the CMA with the assessment.
The comments should be reached by June 3.
In December 2020, British drug manufacturer AstraZeneca agreed to buy Alexion Pharmaceuticals for 175 dollars per share in cash and stock, valuing the Boston-based company at 39 billion dollars.
-
Featured6 days agoInside INEC’s race to prepare for Nigeria’s 2027 elections
-
Latest1 week agoGlobal excitement builds as Healing Streams Live Services returns October 23
-
Featured6 days ago2027: APC unveils nationwide campaign timetable, Tinubu to rally in 12 states
-
Business1 week agoPresident Tinubu and the Low Transport Fares Fiasco
-
Business3 days agoNaira faces exchange rate gap as Dollar hits N1,380 on parallel market
-
Business6 days agoCourt dismisses ₦170m Trade Fair contract claim, says Zenith Bank was not a party
-
Latest6 days agoBreaking: NNPCL raises petrol price to ₦1,405 per litre amid discount controversy
-
Business1 week agoRite Foods targets beverage market growth with LIDA Malt